Skip to Content

IQVIA Holdings Inc - Stock Quote IQV

Rating as of

Morningstar's IQVIA Holdings Inc Stock Analysis

Currency in USD
Is it the right time to buy or sell?
Is it the right time to buy or sell?

1-Star Price


5-Star Price


Economic Moat


Capital Allocation


Narrow-Moat IQVIA Posts Solid Q1 Results, Strong Long-Term Outlook; Maintaining FVE of $276

Rachel Elfman Equity Analyst

Business Strategy and Outlook

| Rachel Elfman |

IQVIA (formerly QuintilesIMS) is the result of the merger of Quintiles, a leading late-stage contract research organization, or CRO, and IMS Health, a dominant player in life sciences data and analytics. The combined company has become an established leader among CROs and in the life sciences data and analytics space. Further, as a result of the merger, the company leads in real-world evidence, in which data from sources such as patient records or medical claims can be used to create clinical evidence for regulatory approval.

Unlock Our Full Analysis With Morningstar Investor

Key Statistics - IQV

IQVIA Holdings Inc's Company Profile

Business Description

IQVIA is the result of the 2016 merger of Quintiles, a leading global contract research organization, and IMS Health, a leading healthcare data and analytics provider. The Research & Development segment focuses primarily on providing outsourced late-stage clinical trials for pharmaceutical, device, and diagnostic firms. The Technology & Analytics segment provides aggregated information and technology services to clients in the healthcare industry, including pharmaceutical companies, providers, payers, and policymakers, as well as data and analytics capabilities for clinical trials, including virtual trials. The company also has a small contract sales business.

4820 Emperor Boulevard
Durham, NC, 27703
T +1 919 998-2000
Industry Diagnostics & Research
Most Recent Earnings Mar 31, 2022
Fiscal Year End Dec 31, 2022
Stock Type Classic Growth
Employees 82,000

IQVIA Holdings Inc's Related News